Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Oncogene. 2021 Jun 22;40(30):4872–4883. doi: 10.1038/s41388-021-01881-8

Figure 2. PARP14 is required for RB phosphorylation and E2F1-target protein expression.

Figure 2.

A-C. Western blots showing the levels of phosphorylated RB at Ser780 upon PARP14 knockdown in RPE-1 (A), MCF7 (B) and HCT116 (C) cells. D. Western blots showing the levels of E2F1 and phosphorylated RB at Thr821/826 upon PARP14 knockdown in RPE-1 cells. E. Western blots showing the levels of E2F1 targets Cyclin A, Cyclin B, Cdc6 and Chk1 upon PARP14 knockdown in RPE-1 cells. F. Cell cycle profiles of RPE-1 WT (left) and RBKO (right) cells after PARP14 knockdown and subsequent treatment with 200ng/mL nocodazole for 24h. G. Quantification showing the percent of RPE-1 WT and RBKO cells in G2/M cell cycle phase upon PARP14 knockdown and subsequent treatment with 200ng/mL nocodazole for 24h. Bars represent the means ± SEM (t-test, unpaired). H. Quantification showing the percent of T47D palbociclib-resistant cells (T47D-R) cells in G1 cell cycle phase upon PARP14 knockdown. Bars represent the means ± SEM (t-test, unpaired).